Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...

A single dose of Ixchiq induced a high and sustained immune response in 99.1% of adolescents, according to Valneva.

Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted for review GSK 's new drug application (NDA) for Blenrep ...

Orbis Medicines and Vivtex have partnered to support the development of next-generation orally dosable macrocycle drugs.

Nura Bio has secured additional $68m in a Series A financing round to advance the development of its neuroprotective ...

The Israeli Ministry of Health granted approval for BeiGene’s TEVIMBRA for unresectable or metastatic oesophageal squamous ...

Ossium Health’s PRESERVE I trial is evaluating the safety and effectiveness of its deep-frozen bone marrow from deceased ...

At the Clinical Trial Supply West Coast 2024 conference, serial biotech entrepreneur Umar Hayat said science should be allowed to advance without political interference.

Catherine Longworth is the Editor for Medical Device Network, covering developments across the medical technology and health ...

Bicara was one of three biotechs that went public last week in one of the busiest biotech IPO windows this year.

The company claims that the FTC’s July 2024 report is riddled with “false and misleading claims” about the PBM industry.

The clinical hold was placed on three studies investigating azenosertib in June after two patients died due to presumed ...